Charles River Labs Reports Q1 Net Loss Driven by $118M Divestiture Charge, Increased Debt, and Strategic Acquisitions
Summary
Charles River Laboratories reported a Q1 net loss of $14.8 million, primarily due to a $118.0 million pre-tax loss from the divestiture of its CDMO and Cell Solutions businesses, alongside a significant increase in long-term debt.
Key Events
-
Q1 Net Loss Reported
The company reported a net loss of $14.8 million, or $0.30 per diluted share, for the three months ended March 28, 2026, a significant decline from a $25.5 million net income in the prior year period. This was primarily driven by a $118.0 million pre-tax loss on the divestiture of CDMO and Cell Solutions businesses.
-
Long-Term Debt Increased
Long-term debt, net and finance leases, increased by $526.8 million to $2.66 billion as of March 28, 2026, from $2.14 billion at December 27, 2025, primarily to fund acquisitions.
-
Strategic Acquisitions Completed
The company completed the acquisition of an additional 79% equity interest in PathoQuest SAS for approximately $60.0 million and the acquisition of certain assets of a Cambodian NHP Supplier for $507.3 million, with $335.0 million paid at closing.
-
Divestiture Activity Continues
The sale of CDMO and Cell Solutions businesses was completed on May 6, 2026, resulting in a $118.0 million pre-tax loss. An agreement was also signed to sell certain European Discovery Services businesses for $145.0 million cash plus contingent payments.
Analysis
This quarterly report reveals a significant shift to a net loss for Charles River Laboratories, primarily due to a substantial pre-tax loss from a divestiture. The company also incurred a notable increase in long-term debt to fund strategic acquisitions, which, while aimed at growth, add to the financial leverage. The ongoing legal challenges related to NHP supply chain and a newly disclosed cybersecurity incident introduce additional layers of risk. While the company is actively managing its portfolio through acquisitions and divestitures and executing a share repurchase program, the immediate financial results and increased debt signal a challenging period, warranting close investor attention to future operational improvements and debt management.
At the time of this filing, CRL was trading at $181.68 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $9B. The 52-week trading range was $131.30 to $228.88. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.